Does OBINUTUZUMAB Cause Aplastic anaemia? 13 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Aplastic anaemia have been filed in association with OBINUTUZUMAB (Gazyva). This represents 0.1% of all adverse event reports for OBINUTUZUMAB.
13
Reports of Aplastic anaemia with OBINUTUZUMAB
0.1%
of all OBINUTUZUMAB reports
0
Deaths
6
Hospitalizations
How Dangerous Is Aplastic anaemia From OBINUTUZUMAB?
Of the 13 reports, 6 (46.2%) required hospitalization, and 1 (7.7%) were considered life-threatening.
Is Aplastic anaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OBINUTUZUMAB. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does OBINUTUZUMAB Cause?
Off label use (1,584)
Neutropenia (1,276)
Febrile neutropenia (955)
Covid-19 (942)
Pyrexia (920)
Thrombocytopenia (889)
Disease progression (831)
Infusion related reaction (789)
Pneumonia (662)
Anaemia (640)
What Other Drugs Cause Aplastic anaemia?
ECULIZUMAB (345)
CYCLOPHOSPHAMIDE (332)
CYCLOSPORINE (331)
METHOTREXATE (281)
BUSULFAN (220)
FLUDARABINE (220)
ETOPOSIDE (186)
VINCRISTINE (173)
CYTARABINE (163)
ELTROMBOPAG OLAMINE (149)
Which OBINUTUZUMAB Alternatives Have Lower Aplastic anaemia Risk?
OBINUTUZUMAB vs OCELLA
OBINUTUZUMAB vs OCRELIZUMAB
OBINUTUZUMAB vs OCRIPLASMIN
OBINUTUZUMAB vs OCTINOXATE\OCTISALATE\ZINC
OBINUTUZUMAB vs OCTINOXATE\OCTOCRYLENE